Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Annals of Hematology|July 30, 2021
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Rita Mazza, Michele Spina, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 StudyPier Luigi Zinzani, Alessandro Broccoli, Daniela Maria Gioia, et al.
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
The Lancet. Oncology|March 18, 2008
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)Pier Luigi Zinzani, Monica Tani, Alessandro Pulsoni, et al.
Hematological Oncology|October 25, 2021
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experienceFulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
Blood Advances|October 1, 2021
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trialUmberto Ricardi, Mario Levis, Andrea Evangelista, et al.
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Pageof 11